News

An article published in Nature sheds light on what India is doing to mitigate the spread of antimicrobial resistance — which has emerged as a major public health threat due to the country’s poorly regulated pharmaceutical industry and a public–private divide in healthcare that has not only contributed to the excessive use of antibiotics but […]

Read More

Out in The National News, an article reveals that India detected its first case of the JN.1 coronavirus sub-variant amid a sharp surge in Covid-19 cases and hospitalizations, thus prompting health authorities to ask states to increase precautionary measures against the spread of infections. OHT’s Dr. Ramanan Laxminarayan comments, “COVID is with us permanently and […]

Read More

Out in the Dhaka Mail, an article covers the “Antimicrobial Resistance and Vaccines Workshop” organized by the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and the Global Antibiotic Resistance Partnership (GARP). Find the article here.

Read More

An article published in the Bangla Tribune covers the “Antimicrobial Resistance and Vaccines Workshop” organized by the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and the Global Antibiotic Resistance Partnership (GARP). Find the article here.

Read More

An article published in the Daily Sun covers the “Antimicrobial Resistance and Vaccines Workshop” organized by the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and the Global Antibiotic Resistance Partnership (GARP), an initiative led by OHT to promote actionable policies to control the spread of drug resistance in Dhaka, Bangladesh. The workshop, funded by the […]

Read More

An article published in The Financial Express covers the “Antimicrobial Resistance and Vaccines Workshop – Bangladesh” held in Dhaka and organized by the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and the Global Antibiotic Resistance Partnership (GARP), an initiative led by OHT to promote actionable policies to control the emergence and spread of drug […]

Read More

An article published in The New York Times covers the exciting story about the groundbreaking oral treatment for gonorrhea, Zoliflodacin, acing its phase 3 clinical trials. The nonprofit, GARDP, developed the antibiotic in collaboration with an American pharmaceutical company called Innoviva Specialty Therapeutics. The nonprofit sponsored the Phase 3 trial of the drug. In exchange, it holds […]

Read More

An article and podcast published in NPR’s Goats and Soda highlights the troubling results of new research published in The Lancet Regional Health – Southeast Asia — the most commonly prescribed antibiotics in Southeast Asia are now only 50% effective at treating sepsis and meningitis in newborns. This is largely due to growing resistance to […]

Read More

In an interview published by the Cambridge Core on behalf of the Society for Healthcare Epidemiology of America, OHT’s Dr. Ramanan Laxminarayan says, “I am optimistic that 20 years from now, we will have addressed this (antimicrobial resistance) in a significant way through a combination of tools, and we’ll look back and say that there […]

Read More